Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥9895.0B | ¥9451.6B | +4.7% |
| Operating Income | ¥133.9B | ¥140.5B | −4.7% |
| Equity-Method Investment Gain (Loss) | - | - | - |
| Ordinary Income | ¥179.2B | ¥182.3B | −1.7% |
| Net Income | ¥159.4B | ¥126.1B | +26.4% |
| ROE | 2.0% | 1.6% | - |
Executive Summary
In Q1 FY2027, Revenue increased while Operating Income declined, and the increase in Net Income was primarily attributable to a temporary boost from gains on the sale of investment securities. Revenue was ¥9,895.0B (+4.7% YoY), Operating Income was ¥133.9B (-4.7%), and Ordinary Income was ¥179.2B (-1.7%). Meanwhile, Net Income increased substantially to ¥159.4B (+26.4%), mainly due to the contribution of ¥62.1B in extraordinary income, centered on ¥60.6B in gains on the sale of investment securities. This does not indicate an improvement in the profitability of the core business. While the Wholesale Business of Prescription Pharmaceuticals and Other Products, the main business, reported higher Revenue and Operating Income, segment profit in the Cosmetics, Daily Necessities, and OTC Pharmaceuticals Wholesale Business declined 19.5%, weighing on the Company-wide Operating Income margin.
Factors Affecting Performance
【Revenue】Revenue was ¥9,895.0B, representing a 4.7% YoY increase. By segment, the Wholesale Business of Prescription Pharmaceuticals and Other Products (63.7% of the composition) increased 5.1%, the Cosmetics, Daily Necessities, and OTC Pharmaceuticals Wholesale Business (33.0%) increased 3.4%, and the Wholesale Business of Veterinary Pharmaceuticals and Food-Processing Raw Materials and Related Businesses (3.3%) increased 9.9%, resulting in higher Revenue across all segments.
【Profit and Loss】Operating Income declined to ¥133.9B (-4.7% YoY). The gross margin was 6.6%, approximately 10bp lower than 6.7% in the same period of the previous year, while the SG&A expense ratio also increased slightly to 5.3%, making cost absorption a challenge. By segment, the Wholesale Business of Prescription Pharmaceuticals and Other Products performed strongly, with segment profit increasing 13.9%, while the Veterinary Pharmaceuticals and Related Businesses segment increased 39.8%. In contrast, the Cosmetics, Daily Necessities, and OTC Pharmaceuticals Wholesale Business posted a substantial 19.5% decline, weighing on Company-wide profit. Ordinary Income was ¥179.2B (-1.7%), with non-operating income of ¥54.8B, including ¥8.0B in dividends received and ¥8.9B in equity-method investment gains and losses, partially mitigating the decline in Operating Income. Net Income increased substantially to ¥159.4B (+26.4%), but this was primarily due to extraordinary income of ¥62.1B, centered on ¥60.6B in gains on the sale of investment securities, rather than an improvement in recurring profitability. Overall, the results represent higher Revenue but lower profit.
Segment Analysis
The Wholesale Business of Prescription Pharmaceuticals and Other Products reported Revenue of ¥6,305.6B (+5.1% YoY) and Operating Income of ¥63.0B (+13.9%), achieving higher Revenue and profit. As the core business, it accounts for 63.7% of Company-wide Revenue, and its profit margin improved to 1.0%. The Cosmetics, Daily Necessities, and OTC Pharmaceuticals Wholesale Business posted higher Revenue of ¥3,269.3B (+3.4%), but Operating Income declined substantially to ¥61.3B (-19.5%), reducing its profit margin to 1.9%. The Wholesale Business of Veterinary Pharmaceuticals and Food-Processing Raw Materials and Related Businesses maintained high growth and profitability, with Revenue of ¥330.9B (+9.9%) and Operating Income of ¥10.7B (+39.8%). However, its contribution to the Company as a whole remains limited because it accounts for only 3.3% of the Revenue composition. The results indicate that deteriorating profitability in the consumer-related businesses is offsetting profit growth in the core business.
Key Financial Indicators
【Profitability】The Operating Income margin was 1.4%, approximately 10bp lower than approximately 1.5% in the same period of the previous year, while the gross margin also declined by approximately 10bp to 6.6%. The Net Income margin was 1.6% on a Net Income basis, exceeding the level in the same period of the previous year, although it includes the contribution from extraordinary income.【Cash Quality】Accounts receivable were ¥8,348.6B, accounting for 43.1% of total assets. Annualized DSO was approximately 77 days, indicating a somewhat lengthy collection cycle for a wholesaler. Inventories were ¥1,948.6B, representing 10.1% of total assets.【Investment Efficiency】ROE was 2.0% on a quarterly actual-results basis, indicating a low level of profit relative to the scale of total assets and net assets. BPS was ¥3,174.07, and basic EPS was ¥66.67 (+44.4% from ¥46.17 in the previous year).【Financial Soundness】The Equity Ratio was 40.9%. Liquidity is secured, with current assets of ¥1兆4,004.5B compared with current liabilities of ¥1兆896.4B, while non-current liabilities were ¥560.7B and represented a small portion of the liability structure.
Cash Flow Analysis
Because individual data from the cash flow statement have not been disclosed, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥2,899.2B, nearly unchanged from ¥2,890.7B in the same period of the previous year, indicating a stable cash position. Meanwhile, accounts receivable increased to ¥8,348.6B from ¥8,078.5B in the same period of the previous year, reflecting an expansion in working capital accompanying Revenue growth. Accounts payable also increased to ¥1兆205.5B from ¥9,845.3B in the same period of the previous year, and the increase in trade payables partially offset the funding burden arising from the increase in accounts receivable. Inventories increased slightly to ¥1,948.6B from ¥1,904.0B in the same period of the previous year. Overall, the Company maintains the typical funding structure of a wholesaler, in which accounts receivable, inventories, and accounts payable all expand alongside Revenue growth, limiting the significant impact on the cash balance.
Earnings Quality
Of the current period's Profit Before Tax of ¥236.99B, the net amount of extraordinary income of ¥62.11B, primarily consisting of ¥60.61B in gains on the sale of investment securities, less extraordinary losses of ¥4.31B, was ¥57.80B, accounting for 24.4% of Profit Before Tax. This component therefore needs to be evaluated separately from recurring profitability. Non-operating income of ¥54.80B was equivalent to 40.9% of Operating Income, with investment income such as ¥8.03B in dividends received and ¥8.93B in equity-method investment gains supporting Ordinary Income. As a result, gains on the sale of investment securities of ¥60.61B accounted for 44.4% of Net Income attributable to owners of the parent of ¥136.46B, indicating limited earnings recurrence. Comprehensive income was only ¥58.70B, substantially below Net Income attributable to owners of the parent, primarily because valuation differences on securities held decreased by ¥99.57B. This indicates that fluctuations in market value represent a source of changes in equity and that the Company is exposed to market-value volatility risk.
Earnings Forecast and Guidance
The full-year Company plan calls for Revenue of ¥3兆9,440B (+3.3% YoY), Operating Income of ¥535.0B (+0.6%), Ordinary Income of ¥675.0B (-10.9%), and Net Income attributable to owners of the parent of ¥430.0B. Q1 progress rates were 25.1% for Revenue and 25.0% for Operating Income, both approximately in line with the standard level of 25%. The Ordinary Income progress rate was slightly higher at 26.5%. Meanwhile, the progress rate for Net Income attributable to owners of the parent was 31.7%, substantially above the standard level; however, this includes gains on the sale of investment securities recorded in Q1 and therefore does not directly indicate an upside relative to the full-year plan. The Company plan itself incorporates a 10.9% YoY decline in Ordinary Income and is conservative, assuming a contraction in non-operating income and expenses. No revision to the earnings forecast had been made as of the end of the current quarter.
Shareholder Returns
The full-year dividend forecast is ¥88.00 per share, unchanged from the announcement date of July 14, 2026. Based on the weighted-average number of shares outstanding during the period of 2億469.9万 shares, estimated total dividends are approximately ¥180B, resulting in a Payout Ratio of approximately 41.9% against the full-year forecast of Net Income attributable to owners of the parent of ¥430.0B. This level is below the general sustainability benchmark of 60%, and assuming the earnings plan, the dividend burden is not excessive. No disclosure regarding share buybacks has been identified.
Risk Factors
-
Deterioration in the profitability of the Cosmetics and Daily Necessities Wholesale Business: Despite Revenue growth of 3.4%, segment profit in this business declined 19.5% YoY. If profitability continues to deteriorate in a business accounting for 33.0% of the Revenue composition, it could offset the profit-growth effect of the Wholesale Business of Prescription Pharmaceuticals and Other Products and delay improvement in Company-wide operating leverage.
-
Lengthening of the accounts receivable collection cycle: Accounts receivable of ¥8,348.6B account for 43.1% of total assets, and annualized DSO is approximately 77 days. In the low-margin wholesale business, a longer collection cycle could tie up working capital and reduce funding efficiency.
-
Market-value volatility risk of securities held: The Company holds investment securities of ¥1,940.5B, and valuation differences declined by ¥99.6B during the current period. This decline caused Comprehensive Income of ¥58.7B to fall substantially below Net Income attributable to owners of the parent of ¥136.5B, indicating a structure in which equity is susceptible to trends in the stock market as a source of changes in capital.
Industry Benchmark (For Reference; Compiled by the Company)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 1.4% | 4.3% (1.7%–6.9%) | −2.9pt |
| Net Income Margin | 1.6% | 3.8% (1.5%–5.1%) | −2.2pt |
Both the Operating Income margin and Net Income margin are below the industry median, indicating that profitability is relatively low even within the wholesale industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 4.7% | 3.1% (-0.6%–11.7%) | +1.6pt |
The Revenue growth rate exceeds the industry median, indicating that the pace of top-line expansion is relatively fast within the industry.
Source: Compiled by the Company
Key Takeaways from the Results
-
While Revenue increased 4.7% YoY, Operating Income declined 4.7%, making the failure of Revenue growth to translate into profit growth a structural characteristic of the results. Both the gross margin and Operating Income margin declined by approximately 10bp, and cost absorption under the low-margin business structure remains an ongoing challenge.
-
The 42.3% increase in Net Income attributable to owners of the parent (+26.4% on a ¥159.4B basis) was substantially driven by a temporary factor, namely the ¥60.6B gain on the sale of investment securities. The high full-year progress rate of 31.7% for Net Income attributable to owners of the parent is likewise attributable to this factor, requiring cautious interpretation as a leading indicator of recurring profit growth.
-
While the core Wholesale Business of Prescription Pharmaceuticals and Other Products continues to achieve higher Revenue and profit, declining profit in the Cosmetics, Daily Necessities, and OTC Pharmaceuticals Wholesale Business is weighing on Company-wide profitability. Going forward, the recovery of profitability in this business and trends in the accounts receivable collection cycle will be key points in evaluating the Company's financial condition.
Theoretical Share Price (Reference Value)
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥2,940 |
| base | ¥2,961 |
| bull | ¥2,998 |
| Calculation Assumption | Value |
|---|---|
| Book Value Per Share (BPS) | ¥3,174 |
| Adjusted Forecast EPS | ¥217.8 |
| Cost of Equity r | 9.27% (10-year Japanese government bond 2.77% + equity risk premium 6.00% + size premium 0.50%) |
| Residual Income Persistence Factor ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 41.9% |
| Forecast EPS Confidence Adjustment | ×1.037 (based on the industry's historical guidance achievement rate) |
| Implied PBR / PER | 0.93x / 13.6x |
Sensitivity: ¥2,879–¥3,046 at ±1% Cost of Equity, and ¥2,954–¥2,966 at ω±0.1.
Notes:
- Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value Per Share.
- Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest-rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee the future share price.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2027 Q1 was a mixed result: sales growth remained solid, but underlying operating profitability weakened and the sharp rise in profit attributable to owners was principally driven by securities-sale gains. Revenue increased 4.7% year on year to ¥989.5bn. Operating income declined 4.7% to ¥13.4bn despite the higher sales base. Ordinary income fell a more modest 1.7% to ¥17.9bn, as net non-operating income improved. Profit before tax increased 27.0% to ¥23.7bn. Profit attributable to owners rose 42.3% to ¥13.6bn, and EPS increased to ¥66.67 from ¥46.17. The principal driver of the pre-tax and net-income acceleration was a ¥60.6bn gain on sale of investment securities, included in extraordinary income. Consequently, reported net-profit growth does not represent a comparable improvement in recurring earnings power. Gross margin contracted by 4bp year on year to 6.6%. Operating margin fell by 13bp to 1.4%, reflecting that the ¥10.6bn increase in gross profit was more than offset by a ¥17.2bn increase in SG&A expenses. The medical prescription-drug wholesale business expanded both sales and segment profit, partially offsetting a material profit decline in cosmetics, daily necessities and OTC-drug wholesale. The animal pharmaceutical and food-processing-materials business posted the fastest segment profit growth and the highest segment margin, albeit from a relatively small revenue base. Liquidity remains adequate, with a 128.5% current ratio and 110.6% quick ratio, while the trade-payables-funded nature of the wholesale model is evident in ¥1,020.5bn of payables. The annualized DuPont ROE is 6.9%, below the 8% reference level, with the low margin rather than balance-sheet leverage being the principal constraint. Full-year guidance was maintained, and Q1 operating-income progress of 25.0% is exactly in line with the standard seasonal benchmark. The 31.7% progress rate for profit attributable to owners is ahead of the normal 25% pace, but this outperformance is substantially explained by non-recurring securities gains. Near-term attention should therefore center on whether the company can restore margin expansion in the cosmetics/OTC operation and translate sales growth into recurring operating-income growth.
Profitability Analysis
The reported annualized 6.9% ROE decomposes into a 1.4% net profit margin, 2.043x asset turnover and 2.45x financial leverage. High asset turnover is structurally consistent with pharmaceutical wholesale distribution, but its benefit is constrained by very thin profitability. Financial leverage supports ROE, although the 1.45x debt-to-equity ratio is not aggressive relative to the 2.0x warning threshold. The largest adverse operating change was margin compression: gross margin declined from approximately 6.64% to 6.61%, while operating margin declined from approximately 1.49% to 1.35%. Gross profit increased only 1.6% to ¥65.7bn versus 4.7% revenue growth, indicating unfavorable gross-margin mix or pricing/cost pressure. SG&A increased 3.4% to ¥52.3bn, outpacing gross-profit growth, although it grew more slowly than revenue. Salaries and allowances rose 2.1% to ¥19.1bn, while rent expense increased 13.7% to ¥1.6bn. The SG&A burden consequently absorbed the gross-profit increase and reduced operating income by ¥0.7bn. The 1.4% EBIT margin triggers the low-operating-efficiency quality alert; while low margins are characteristic of regulated, high-volume pharmaceutical distribution, the year-on-year deterioration reduces earnings resilience against rebate, price-revision and labor-cost pressures. The low 6.6% gross-margin alert has the same industry context: it reflects the wholesale model rather than necessarily weak execution, but leaves limited room for cost inflation or competitive price concessions. Interest coverage of 4,462x is exceptionally strong because interest expense was only ¥0.03bn, so financing cost is not a material current-period earnings constraint. The five-factor tax burden of 0.576 is based on profit attributable to owners relative to profit before tax and is affected by non-controlling interests; the income-tax expense-to-profit-before-tax calculation is 32.7%. Accordingly, the high-tax-burden alert should be interpreted cautiously rather than as evidence of a cash-tax rate above 40%.
Growth Assessment
Revenue growth was broad-based across all three reported segments. The core business, medical prescription-drug wholesale, increased external revenue 5.1% to ¥6,295.6bn and segment profit 13.9% to ¥63.0bn; its segment margin improved to 1.0% from 0.9%. Cosmetics, daily necessities and OTC-drug wholesale increased revenue 3.4% to ¥3,268.5bn, but segment profit declined 19.5% to ¥61.3bn and margin compressed to 1.9% from 2.4%. This segment was the principal source of consolidated operating-income pressure. Animal pharmaceuticals and food-processing-materials wholesale increased revenue 9.9% to ¥330.9bn and segment profit 39.8% to ¥10.7bn, with margin improving to 3.2% from 2.5%. Segment profit before corporate-cost allocation declined 3.0% to ¥135.1bn, and higher unallocated corporate costs further reduced consolidated operating income. Full-year revenue guidance of ¥3,944.0bn implies 3.3% growth, and Q1 progress is 25.1%, consistent with the 25% seasonal benchmark. Operating-income progress is 25.0% against the ¥53.5bn target, also exactly on the standard pace. Ordinary-income progress is 26.5% against the ¥67.5bn target, 1.5 percentage points ahead of the standard pace. Profit attributable to owners has reached 31.7% of the ¥43.0bn full-year forecast, 6.7 percentage points above the standard pace, but this is not a clean indicator of recurring upside because of the securities-sale gain. Maintained guidance indicates management has not changed its full-year assumptions.
Financial Health
The balance sheet is liquid for a wholesale operator. Current assets of ¥1,400.5bn exceeded current liabilities of ¥1,089.6bn, producing working capital of ¥310.8bn and a 128.5% current ratio. The 110.6% quick ratio indicates that current obligations are covered even excluding inventory, reducing near-term maturity-mismatch risk. Cash and deposits were ¥289.9bn, while receivables were ¥834.9bn and inventories were ¥194.9bn. Trade payables of ¥1,020.5bn are the dominant liability, consistent with the company’s intermediary distribution role. The 1.45x debt-to-equity ratio is elevated versus a conservative 1.0x benchmark but remains below the 2.0x aggressive-financing warning threshold. Total liabilities represented 59.1% of assets, while total equity was ¥791.7bn. Owners' equity was ¥649.7bn and non-controlling interests were ¥142.0bn. Goodwill was only ¥7.6bn, equivalent to 1.0% of equity and 0.4% of assets, indicating limited balance-sheet dependence on acquisition value retention. Intangible assets were 2.0% of assets, also well below concentration benchmarks. Net defined-benefit liability was ¥12.8bn and should remain monitored as a long-term funding obligation, although it is modest relative to equity.
Notable B/S Changes
Accounts receivable: +¥27.0bn (+3.3%) to ¥834.9bn - receivables expanded with sales; annualized DSO of 77 days warrants monitoring of collection efficiency. Accounts payable: +¥36.0bn (+3.7%) to ¥1,020.5bn - supplier financing increased faster than receivables, supporting wholesale working-capital funding. Investment securities: -¥18.4bn (-8.7%) to ¥194.1bn - the decline coincided with a ¥60.6bn securities-sale gain and negative valuation movements, highlighting portfolio and market-value sensitivity. Accumulated other comprehensive income: -¥9.1bn (-13.4%) to ¥59.0bn - mainly reflects weaker securities valuation reserves and reduced comprehensive income.
Cash Flow Quality
The earnings mix indicates lower underlying earnings quality than the headline 42.3% growth in profit attributable to owners suggests. Operating income declined 4.7% and ordinary income declined 1.7%, whereas profit before tax increased 27.0% because extraordinary income exceeded extraordinary loss by ¥57.8bn. The ¥60.6bn gain on sale of investment securities was the dominant extraordinary item. This gain is non-recurring and should not be treated as operating cash-generative performance. Equity-method earnings of ¥8.9bn and dividend income of ¥8.0bn provided meaningful non-operating support to ordinary income. Receivables increased ¥27.0bn year on year to ¥834.9bn, and the quality alert identifies annualized DSO of 77 days, above the 60-day reference threshold. Extended collection days can increase working-capital funding needs and credit exposure, although sizeable receivables are structurally normal in pharmaceutical wholesale. Trade payables rose ¥36.0bn year on year to ¥1,020.5bn, exceeding the receivables increase and supporting the operating working-capital structure. The decline in total comprehensive income to ¥58.7bn from ¥98.0bn, despite higher net income, was largely associated with negative valuation differences on securities and underscores market-value sensitivity in the investment portfolio.
Dividend Sustainability
The maintained full-year dividend forecast is ¥88 per share. Against forecast EPS of ¥210.06, the implied dividend-only payout ratio is 41.9%, below the 60% sustainability reference level. The projected dividend is therefore covered by forecast earnings on a stated basis. Q1 EPS of ¥66.67 represents 31.7% of forecast EPS, aided by the non-recurring gain on sale of investment securities. Dividend capacity should consequently be assessed primarily against full-year recurring operating and ordinary earnings rather than Q1 reported profit alone. The company has not changed its dividend forecast since the July 14 disclosure. Treasury shares totaled 11.3 million shares, or approximately 5.2% of issued shares, but no current-period repurchase amount is provided; dividend coverage is therefore assessed on dividends only rather than a total return ratio. The moderate payout ratio and adequate liquidity provide a supportive base for the stated dividend policy.
Risk Assessment
Business risks include Margin risk: a 13bp decline in operating margin to 1.4% demonstrates the sensitivity of earnings to small changes in purchase conditions, reimbursement-related pricing, rebates and selling prices., Cosmetics, daily necessities and OTC-drug wholesale risk: segment profit fell 19.5% despite 3.4% sales growth, indicating adverse mix, pricing or cost pressure in the second-largest earnings contributor., Receivables and counterparty risk: annualized DSO of 77 days exceeds the 60-day reference point, increasing funding needs and exposure to delayed collection., Industry-specific pharmaceutical distribution risk: public reimbursement and drug-price revisions, manufacturer terms, logistics labor costs and retailer/pharmacy consolidation can pressure already thin wholesale margins., Investment-market risk: the securities portfolio was ¥194.1bn and negative securities valuation movements reduced comprehensive income, creating exposure to equity-market volatility..
Financial risks include The 1.45x debt-to-equity ratio is above a conservative 1.0x benchmark, although it remains below the 2.0x aggressive-financing threshold., Current liabilities of ¥1,089.6bn substantially exceed cash balances, making continued receivable collection and supplier-credit availability important to liquidity management., Net defined-benefit liability of ¥12.8bn exposes equity and future expenses to actuarial and asset-return movements..
Key concerns include Headline owner-profit growth is materially flattered by the ¥60.6bn gain on sale of investment securities; recurring operating income declined., The low operating-efficiency alert is material because a 1.4% EBIT margin provides little buffer against modest gross-margin or SG&A deterioration., The low gross-margin alert is structurally consistent with wholesale distribution but becomes more consequential when gross profit grows slower than revenue., The high-tax-burden alert requires careful interpretation: the stated 0.576 burden reflects owner earnings relative to pre-tax income, while the reported income-tax expense-to-pre-tax-income rate is 32.7%..
Investment Implications
Key takeaways include Sales growth and improved profitability in prescription-drug wholesale demonstrate resilience in the core business., The cosmetics/OTC segment's profit decline is the principal operational issue because it offset gains in the core and smaller animal-related businesses., Reported Q1 net income materially exceeds the run-rate implied by operating income because of a non-recurring securities-sale gain., Liquidity is adequate and goodwill-related balance-sheet risk is low., Full-year operating-income guidance appears seasonally on track, while the above-normal net-income progress rate should not be extrapolated without adjusting for extraordinary gains..
Metrics to watch include Consolidated gross margin and operating margin, Cosmetics, daily necessities and OTC-drug wholesale segment margin, Annualized DSO and the relationship between receivables and trade payables, Recurring ordinary income excluding investment-related gains, Investment securities valuation movements and future gains or losses on disposals, Progress versus the ¥53.5bn full-year operating-income forecast.
Regarding relative positioning, Medipal exhibits the high-turnover, low-margin and supplier-financed balance-sheet profile typical of Japanese pharmaceutical wholesalers. Its annualized 6.9% ROE is supported by 2.043x asset turnover and 2.45x leverage, but remains constrained by a 1.4% net margin and is below the stated 8% ROE reference level. Low goodwill and strong interest coverage are relative balance-sheet strengths, whereas recurring margin recovery is more important than one-off investment gains for comparative earnings quality.